Whalesbook
Veerhealth Care Limited ka board 28 March, 2026 ko aamne-saamne baithkar company ke liye capital (PUNJI) kaise judayi jaaye, is par charcha karega. Company ne yeh kadam apne vistar aur growth plans ko poora karne ke liye uthaya hai. Is baithak se pehle, company ne apne shares ki trading 20 March, 2026 se band kar di hai, jo baithak khatm hone ke 48 ghante baad phir se shuru hogi.
Capital judane ka yeh faisla Veerhealth Care ke vistar aur business badhane ki pratibaddhta ko darshata hai. Paisa judane se company ko naye projects shuru karne, utpadan kshamata badhane ya bazaar mein apni position mazboot karne mein madad milegi. Investors yeh jaanana chahenge ki capital kis tarah se judayi jayegi aur iska company ke financial structure aur future earnings par kya asar padega.
Pehle Niyati Leasing Limited ke naam se jaani jaane wali Veerhealth Care ne 2013 mein Ayurvedic medicines aur cosmetics ke business mein kadam rakha tha. Company ne personal care aur oral care products ke liye commercial orders haasil kiye hain. Ek badi uplabdhi December 2024 mein USFDA assessment ka closure raha, jisne US bazaar ke darwaze khol diye hain. Veerhealth Care ka lakshya March 2027 tak INR 100 crore ka turnover hasil karna hai. Company pehle bhi INR 25 crore ka Rights Issue consider kar chuki hai. Financial Year 2024 ki chauthi (Q4) mein, company ki total income INR 1,461.29 lakhs rahi aur EBITDA margin 13.70% tha.
Jo tarika capital judane ke liye chuna jayega, jaise ki equity shares, convertible securities, ya koi aur financial tool, woh turant asar dalege. In faislon se existing shareholders ke shareholding mein kami aa sakti hai ya company par karz badh sakta hai, jo earnings per share (EPS) aur overall capital structure ko prabhavit kar sakta hai.
Investors kai baaton par nazar rakhe hue hain. Promoter holding ghatkar 30% ho gayi hai, jisne governance aur strategic decision-making par sawaal khade kiye hain. Company ki efficiency metrics bhi sudhar ki maang karte hain, jismein Return on Equity (ROE) 1.77% aur Return on Capital Employed (ROCE) 2.82% hai. Lagatar profit hone ke bawajood, Veerhealth Care ne ab tak koi dividend nahi diya hai, jo shareholders ke liye ek chinta ka vishay hai.
Veerhealth Care, pharmaceutical sector mein kaam karti hai, jo ki ek competitive field hai aur jisme Sun Pharma aur Divi's Labs jaise bade players hain. Lagbhag ₹40 crore ke market capitalization ke saath, Veerhealth Care ki position in badi companies se alag hai. Yeh Bajaj Healthcare Ltd. jaise mid-cap players se muqabla karti hai.
Investors 28 March ki board meeting ke parinaam ka intezaar karenge, jisse capital judane ke tarike aur kul rakam ki spashtata milegi. Iske baad shareholders se kisi bhi jaruri approval, jo ki Extra Ordinary General Meeting (EGM) ya postal ballot ke zariye ho sakta hai, woh bhi mahatvapurna hoga. Antimat safalta is baat par nirbhar karegi ki judaaye gaye funds ko company ki financial performance aur growth trajectory ko badhane mein kitna prabhavi dhang se istemaal kiya jaata hai, khas kar USFDA approval ka fayda uthate hue.